Clinical impact of the balance score in CLL. (A-B) Survival analyses in the ES cohort using validation cases profiled with expression arrays: Kaplan-Meier curves for TTFT, stratifying patients into 4 groups based on balance score quartiles, with P value from the log-rank test (A); multivariate Cox regression incorporating the balance score, Binet stage, IGHV mutational status, age, and sex as predictors, with TTFT as the end point (B). (C) Multivariate Cox regression on ES cohort cases profiled with RNA-seq (78 overlapping with expression arrays), using the balance score, Binet stage, and IGHV mutational status as predictors of TTFT. (D) Analysis of the DE1 cohort profiled with RNA-seq, using multivariate Cox regression with balance score, IGHV status, and TP53 alterations as predictors of TTFT. (E) Multivariate Cox regression on the US3 cohort profiled with RNA-seq, with balance score and IGHV status as predictors of TTFT. (F) Multivariate Cox regression on the DE2 cohort profiled for protein abundance, using balance score and IGHV mutational status as TTFT predictors. P values in panels B-F were calculated with the Wald test. The balance score was standardized as a z score for consistent comparison and interpretation across all analyses.